Nautilus Biotechnolgy, Inc. cash flow to debt ratio of -168.88% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Nautilus Biotechnolgy, Inc.'s free cash flow has increased -15.17% from $-61.27M last year to $-51.97M, signaling increasing performance

Nautilus Biotechnolgy, Inc.'s debt to equity ratio is 0.21, which means that the company's assets are healthy financed, signaling financial stability.

Nautilus Biotechnolgy, Inc.'s debt has increased relative to shareholder equity from 0.15 last year to 0.21 today, signaling weakened financials

Nautilus Biotechnolgy, Inc. has a net cash position, so leverage is healthy.

Nautilus Biotechnolgy, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Nautilus Biotechnolgy, Inc. has insufficient data to evaluate this check.

Nautilus Biotechnolgy, Inc.'s short-term assets of $105.96M exceed its short-term liabilities of $7.95M

Nautilus Biotechnolgy, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Nautilus Biotechnolgy, Inc.'s return on equity of -37.58%, is lower than 15.00%, indicating bad performance

Nautilus Biotechnolgy, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Nautilus Biotechnolgy, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Nautilus Biotechnolgy, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Nautilus Biotechnolgy, Inc. has negative free cash flow, indicating cash burn

Nautilus Biotechnolgy, Inc.'s yearly earnings has increased -16.64% since last year from $-70.78M to $-59.00M, signaling increasing performance

Nautilus Biotechnolgy, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -39.50% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Nautilus Biotechnolgy, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Nautilus Biotechnolgy, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Nautilus Biotechnolgy, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Nautilus Biotechnolgy, Inc. has insufficient data to evaluate this check.

Nautilus Biotechnolgy, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Nautilus Biotechnolgy, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Nautilus Biotechnolgy, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Nautilus Biotechnolgy, Inc. has insufficient data to evaluate this check.

Nautilus Biotechnolgy, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Nautilus Biotechnolgy, Inc. has a price-to-book ratio of 0.84x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Nautilus Biotechnolgy, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue